| 0.8759 -0.059 (-6.33%) | 03-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.36 | 1-year : | 1.59 |
| Resists | First : | 1.16 | Second : | 1.36 |
| Pivot price | 0.61 |
|||
| Supports | First : | 0.73 | Second : | 0.47 |
| MAs | MA(5) : | 0.68 |
MA(20) : | 0.61 |
| MA(100) : | 1.66 |
MA(250) : | 4.26 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 46.2 |
D(3) : | 33.7 |
| RSI | RSI(14): 57.6 |
|||
| 52-week | High : | 17.79 | Low : | 0.47 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ HCWB ] has closed above the upper band by 2.8%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 43% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.95 - 0.95 | 0.95 - 0.96 |
| Low: | 0.69 - 0.7 | 0.7 - 0.7 |
| Close: | 0.87 - 0.88 | 0.88 - 0.88 |
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Tue, 17 Mar 2026
HCW Biologics Closes Exclusive Worldwide License for HCW11-006 - A High Potential Fusion Immunotherapeutic - Investing News Network
Tue, 17 Mar 2026
HCW Biologics Closes Exclusive Global License for HCW11-006, Receives Upfront Payment - TradingView
Tue, 17 Mar 2026
[8-K] HCW Biologics Inc. Reports Material Event | HCWB SEC Filing - Form 8-K - Stock Titan
Tue, 17 Mar 2026
New fusion immunotherapy deal brings HCW Biologics $7M upfront - Stock Titan
Tue, 17 Mar 2026
HCWB stock soars pre-market on positive research results for CAR-T cell therapy - MSN
Tue, 17 Mar 2026
HCWB HCW Biologics (NASDAQ) +81% pre market 17 Mar 2026: CAR-T paper lifts volume - Meyka
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 2.4e+006 (%) |
| Held by Institutions | 10 (%) |
| Shares Short | 21 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.16e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -21 % |
| Return on Assets (ttm) | 95.2 % |
| Return on Equity (ttm) | -31.7 % |
| Qtrly Rev. Growth | 422030 % |
| Gross Profit (p.s.) | -121.9 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 106848 |
| Qtrly Earnings Growth | -13.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.87 |
| Dividend | 0 |
| Forward Dividend | 23760 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|